BACKGROUND: Slow pathway modification (SPM) is the therapy of choice for AV-nodal reentry tachycardia (AVNRT). When AVNRT is not inducible, empirical ablation can be considered, however, the outcome in patients with two AV nodal echo beats (AVNEBs) is unknown. METHODS: Out of a population of 3003 patients who underwent slow pathway modification at our institution between 1993 and 2013, we retrospectively included 32 patients with a history of symptomatic tachycardia, lack of paroxysmal supraventricular tachycardia (pSVT) inducibility but occurrence of two AVNEBs. RESULTS: pSVT documentation by electrocardiography (ECG) was present in 20 patients. The procedural endpoint was inducibility of less than two AVNEBs. This was reached in 31 (97%) patients. Long-term success was assessed by a telephone questionnaire (follow-up time 63±9 months). A total 94% of the patients benefited from the procedure (59% freedom from symptoms; 34% improvement in symptoms). Among those patients in whom ECG documentation was not present, 100% benefited (58% freedom from symptoms, 42% improvement). CONCLUSION: This is the first collective analysis of a group of patients presenting with symptoms of pSVT and inducibility of only two AVNEBs. Procedural success and clinical long-term follow-up were in the range of the reported success rates of slow pathway modification of inducible AVNRT, independent of whether ECG documentation was present. Thus, SPM is a safe and effective therapy in patients with two AVNEBs.
BACKGROUND: Slow pathway modification (SPM) is the therapy of choice for AV-nodal reentry tachycardia (AVNRT). When AVNRT is not inducible, empirical ablation can be considered, however, the outcome in patients with two AV nodal echo beats (AVNEBs) is unknown. METHODS: Out of a population of 3003 patients who underwent slow pathway modification at our institution between 1993 and 2013, we retrospectively included 32 patients with a history of symptomatic tachycardia, lack of paroxysmal supraventricular tachycardia (pSVT) inducibility but occurrence of two AVNEBs. RESULTS: pSVT documentation by electrocardiography (ECG) was present in 20 patients. The procedural endpoint was inducibility of less than two AVNEBs. This was reached in 31 (97%) patients. Long-term success was assessed by a telephone questionnaire (follow-up time 63±9 months). A total 94% of the patients benefited from the procedure (59% freedom from symptoms; 34% improvement in symptoms). Among those patients in whom ECG documentation was not present, 100% benefited (58% freedom from symptoms, 42% improvement). CONCLUSION: This is the first collective analysis of a group of patients presenting with symptoms of pSVT and inducibility of only two AVNEBs. Procedural success and clinical long-term follow-up were in the range of the reported success rates of slow pathway modification of inducible AVNRT, independent of whether ECG documentation was present. Thus, SPM is a safe and effective therapy in patients with two AVNEBs.
Authors: Felix Konrad Wegner; Nils Bögeholz; Patrick Leitz; Gerrit Frommeyer; Dirk Georg Dechering; Simon Kochhäuser; Philipp Sebastian Lange; Julia Köbe; Kristina Wasmer; Gerold Mönnig; Lars Eckardt; Christian Pott Journal: Clin Cardiol Date: 2017-11-22 Impact factor: 2.882
Authors: Henrike Siebels; Christian Sohns; Jan-Hendrik Nürnberg; Jürgen Siebels; Klaus Langes; Joachim Hebe Journal: J Interv Card Electrophysiol Date: 2018-05-15 Impact factor: 1.900
Authors: Felix K Wegner; Simon Kochhäuser; Gerrit Frommeyer; Philipp S Lange; Christian Ellermann; Patrick Leitz; Patrick Müller; Julia Köbe; Lars Eckardt; Dirk G Dechering Journal: Clin Res Cardiol Date: 2021-05-07 Impact factor: 5.460
Authors: Shqipe Gerguri; Nikesh Jathanna; Tina Lin; Patrick Müller; Lukas Clasen; Jan Schmidt; Muhammed Kurt; Dong-In Shin; Christian Blockhaus; Malte Kelm; Alexander Fürnkranz; Hisaki Makimoto Journal: Eur J Med Res Date: 2018-03-27 Impact factor: 2.175